1st Oct 2014 08:22
LONDON (Alliance News) - Cyprotex PLC said Wednesday that it had expanded its toxicology facility to include high content 3D tissue analysis and advanced mitochondrial toxicity analysis after buying new instruments.
Cyprotex bought new instruments including a Thermo Scientific ArrayScan XTI high-content screening platform and a Seahorse XF extracellular flux analyser. These instruments have allowed the company to provide greater specialisation in key areas of toxicology, and expand into pharmacology efficacy research.
This in turn will potentially open up new segments of the pharmaceutical market, Cyprotex said.
"Understanding the mechanisms of toxicology of new therapeutics remains a challenging area. Cyprotex is committed to research in this field to help our clients bring safer drugs to the market," said Chief Executive Anthony Baxter in a statement. "By investing in the ArrayScanTM XTI and the Seahorse XFe we are equipped with some of the latest cutting-edge technologies, allowing us to expand our current offerings into key specialist areas."
Shares in Cyprotex were trading down 1.5% at 50.24 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
CRX.L